STOCK TITAN

RegeneRx Issues Update on ARISE-3 Trial

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) announced updates on its ARISE-3 phase 3 dry eye clinical trial via its website. This information was provided by GtreeBNT during their shareholder meeting held on March 19, 2021. RegeneRx focuses on developing therapeutic peptides for tissue protection and regeneration, with three drug candidates in clinical trials and multiple strategic licensing agreements worldwide. The company holds several patents and patent applications related to its products, indicating a robust pipeline for future growth.

Positive
  • RegeneRx has three drug candidates in clinical development, indicating progress in its pipeline.
  • The company has four active strategic licensing agreements across various regions, enhancing market reach.
  • Patents and applications cover its products in many countries, providing a competitive edge.
Negative
  • None.

ROCKVILLE, Md., March 22, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the estimated timing of the statistical and regulatory plan for its phase 3 dry eye clinical trial (ARISE-3). This summary was provided to RegeneRx by GtreeBNT, the operating entity of its U.S. joint venture, ReGenTree LLC and sponsor of the ARISE-3 trial, which was generated at GtreeBNT's shareholder meeting on Friday March 19, 2021: http://www.regenerx.com/March-22-2021-Update-on-ARISE-3-Statistical-and-Regulatory-Plan or navigate to RegeneRx's home page at http://www.regenerx.com.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair, and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac/neuro and dermal indications, four active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and the EU, and has patents and patent applications covering its products in many countries throughout the world.

Forward Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, but are not limited to, information on phase 3 trial results, competitive products, statements from us, or our U.S. joint venture partner, GtreeBNT, Ora, Inc. and its biostatistics affiliates, or derived from independent market research reports regarding strategic and research partnerships, status of clinical trials, reclassification of our drug candidates from drugs to biologics, regulatory applications and approvals, the development and value of our drug candidates, and the use of our drug candidates to treat various conditions. All forward-looking statements are expectations and estimates based upon information obtained and/or calculated by the Company or its joint venture partner and its affiliates at this time and are subject to change. Moreover, there is no guarantee any clinical trial will be successful or confirm previous clinical results. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2020, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this shareholder letter represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

 

Cision View original content:http://www.prnewswire.com/news-releases/regenerx-issues-update-on-arise-3-trial-301252879.html

SOURCE RegeneRx Biopharmaceuticals, Inc.

FAQ

What is the latest update on RegeneRx's ARISE-3 trial for dry eyes?

RegeneRx provided an update on its phase 3 ARISE-3 dry eye clinical trial on March 22, 2021.

Who is the sponsor of the ARISE-3 trial?

The ARISE-3 trial is sponsored by GtreeBNT, the operating entity of RegeneRx's U.S. joint venture, ReGenTree LLC.

What is RegeneRx Biopharmaceuticals focused on?

RegeneRx is focused on developing therapeutic peptides for tissue protection, repair, and regeneration.

When was the shareholder meeting held that discussed the ARISE-3 trial?

The shareholder meeting discussing the ARISE-3 trial took place on March 19, 2021.

What is the stock symbol for RegeneRx Biopharmaceuticals?

The stock symbol for RegeneRx Biopharmaceuticals is RGRX.

REGENERX BIOPHARMS INC

OTC:RGRX

RGRX Rankings

RGRX Latest News

RGRX Stock Data

78.14k
806.79k
44.14%
0.03%
Biotechnology
Healthcare
Link
United States of America
Rockville